Apnimed (APMD) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| B of A Securities | Initiated Coverage | Buy | $41.00 | Aug 25, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | — | Aug 25, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $50.00 | Aug 25, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $60.00 | Aug 25, 2026 |
Frequently asked questions
What is the price target for APMD stock?
The average 12-month analyst price target for Apnimed (APMD) is $50.33, with a high estimate of $60.00 and a low of $41.00, across 3 analysts.
Is APMD a buy, sell, or hold?
Analysts covering Apnimed currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for APMD?
The average price target of $50.33 implies 91.75% upside from the last price of $26.25.
What is the latest analyst rating on APMD?
On Aug 25, 2026, B of A Securities initiated coverage of Apnimed at Buy with a price target of $41.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.